Novavax Stock News

Novavax just announced promising news that could help lead to much-needed income later this year. The vaccine maker has expressed concerns about its ability to survive.

Shares of COVID-19 vaccine makers soared after reports suggest that the Biden administration will start a campaign urging citizens to vaccinate themselves with updated shots vaccine in the upcoming fa

Novavax's vaccine and new shots from Pfizer and Moderna are expected to roll out in the U.S. within weeks, pending potential approvals from the FDA.

Michael Yee, Jefferies senior biotech analyst, joins 'Squawk Box' to discuss the market performance of Covid vaccine stocks, as companies prepare to roll out new modified boosters to combat new varian

Novavax (NASDAQ: NVAX ) stock led the surge of Covid-19 vaccine stocks, offering an updated vaccine it says is effective against new variants. The company said its new protein-based vaccine generated

Novavax Inc. NVAX, +13.03% said Tuesday that its updated COVID-19 vaccine has shown promise against newer strains of the virus. In small animal and non-human primate studies, the protein-based shot de

Novavax Inc said on Tuesday its updated protein-based COVID-19 vaccine generated neutralizing antibody responses to the "Eris" subvariant in preclinical studies.

Last week, Moderna and BioNTech partner Pfizer said their new COVID vaccines work against the current dominant strain of omicron growing across the U.S. Today, the Biden administration announced a cam

One of the stock subgroups that's gaining significant attention in today's market is that of Covid-19 vaccine makers. Among today's biggest winners is beaten-down Novavax (NASDAQ: NVAX ).

Novavax, Moderna, Pfizer and its partner BioNTech are slated to roll out new shots designed to target the omicron subvariant XBB.1.5 this fall.

The drugmakers designed their updated coronavirus shots to target the omicron subvariant XBB.1.5, which is slowly declining nationwide.

Novavax posted a surprising profit last quarter as revenue more than doubled. However, the COVID-vaccine maker might not generate much revenue next quarter.

Investors who've dipped their toe into the waters of biotech stocks know that the chances of these stocks crashing and burning is certainly higher than with most sectors. Failure is incredibly common

Three US pharmaceutical companies, Pfizer Inc (NYSE:PFE), Moderna Therapeutics Inc (NASDAQ:MRNA), and Novavax Inc, are gearing up to release updated Covid-19 vaccines this autumn. The new jabs are de

Novavax's prospects in the coronavirus vaccine market look dim. Sage Therapeutics' recent regulatory news was a major blow to its prospects.